Assessing multiple biomarkers such as TLR4, MyD88 and MAD2 which give greater insight into the pathological makeup of a patient’s tumour may help to direct therapies and more suitable treatment combinations in order to improve overall outcome. Here, MAD2L1 is linked to neoplasm.